Kornimate/medical-research-clean huggingface dataset:
a phase 2 study to assess the pharmacokinetics of bevirimat 100 mg tablets given to hiv-1 positive patient for 15 days

Conditions: HIV-1 Infection

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to hiv-positive individuals.


Eligibility criteria:
inclusion criteria: * have documentation of hiv-1 infection in their medical records (documentation of any prior plasma viremia is acceptable). * have a cd4+ lymphocyte count \>/= 100 cells/mm3. * have a screening plasma hiv-1 rna value, measured by the roche amplicor assay, of \<400 copies/ml. * be receiving an arv therapy regimen containing at least 3 drugs which has been unchanged for at least 8 weeks prior to screening, and which is to be continued through day 15 of the study. * be informed of the nature of the study and provide written informed consent. * be legally competent and able to communicate effectively with study personnel. * be able and willing to comply with outpatient visits. exclusion criteria: * presence of any acute illness within 14 days prior to study entry. * presence of any aids-related opportunistic infection (category c according to the cdc classification system for hiv-1 infection, 1993 revised version) that is unstable in the investigator's opinion or diagnosed in the 30 days prior to study entry. * patients who are, in the opinion of the investigator, unable to comply with the dosing schedule and protocol evaluations. * patients with malabsorption syndromes affecting drug absorptions (e.g. crohn's disease, chronic pancreatitis). * patients with systolic blood pressure \ 160 mmhg or diastolic blood pressure \ 110 mmhg. * a history of seizures (excluding pediatric febrile seizures) or current administration of prophylactic anti-seizure medication for the indication of seizures or seizure-related conditions. * a history of cerebrovascular accident (cva) or transient ischemic attacks (tia). * patients who have received radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to first dose of study drug. * patients who have received treatment with immunomodulating agents such as il-2, alpha-interferon, beta-interferon, or gamma-interferon within 4 weeks prior to first dose of study drug. * receipt of an investigational drug or product, or participation in a drug study within a period of 30 days prior to receiving study medication. * bupropion-containing products require at least a 14-day washout period and will not be approved for co-administration. * rifampin or other rifamycin products require at least a 28-day washout period and will not be approved for coadministration.
biomarkers in idiopathic juvenile arthritis

Conditions: Idiopathic Juvenile Arthritis

Summary: juvenile idiopathic arthritis (jia) is the most common form of arthritis in children. the etiology is unknown. several types of arthritis fall under the jia heading. oligoarticular jia with antinuclear antibodies affects about half of all children. there 's no specific markers. our purpose is to identify new markers in this pathology. the protoarray®human protein microarray allows rapid and efficient detection of protein interaction using a suitable protein or small molecule probe. the investigators hope so detect novel potential autoantigen biomarkers specific in jia.

we select 10 patients with inclusion criteria and 10 controls. we analyse their blood sample (5ml). the protoarray® microarray allows to detect novel protein-protein interactions, to rapidly perform serum profiling using a sensitive method to detect potential autoantigen biomarkers. the protoarray® human protein microarray is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening.

Eligibility criteria:
inclusion criteria for experimental group : * child age from 2 to 16 years * oligoarticular jia with antinuclear antibodies * with or without uveitis exclusion criteria for experimental group : * immunosuppressive and biological therapy inclusion criteria for control group : * child age from 2 to 16 years
immunogenicity induced by covid-19 vaccines in mexican population

Conditions: COVID-19 Vaccine

Summary: to determine the gene expression of anti-spike igg through pcr-rt in patients vaccinated with the 4 types of vaccines available in mexico oxford/astrazeneca (chadox1 ncov-19), centro nacional gamaleya (sputnik v), pfizer/biontech (bnt162b2) and sinovac (coronavac).

80 subjects with full vaccination schedule will be included, 20 per group to know the gene expression of igg anti-spike through pcr-rt in patients vaccinated with the 4 types of vaccines available in mexico oxford/astrazeneca (chadox1 ncov-19), centro nacional gamaleya (sputnik v), pfizer/biontech (bnt162b2) and sinovac (coronavac).

Eligibility criteria:
inclusion criteria: 1. - mexican people. 2. - over 18 years of age. 3. - with complete vaccination schedule against covid-19. 4. - allowing peripheral blood samples to be taken. 5. - to sign an informed consent form. 6. - to agree to participate in the protocol. exclusion criteria: 1. - persons with incomplete vaccination schedule against covid-19. 2. - persons who have 30 +/- 5 days of having completed the vaccination scheme against covid-19. 3. - people under treatment with any immunosuppressive drug. 4. people who refuse to sign the informed consent form.
the effects of swimming on elderly women with stage-2 hypertension

Conditions: Menopause; Hypertension

Summary: aging is associated with progressive decreases in arterial health and function as well as overall fitness. it is crucial to prevent or reduce the negative effects of aging on the vasculature and fitness components by implementing appropriate lifestyle interventions, such as exercise training. we examined the effects of a swimming (swm) regimen on arterial stiffness (pulse wave velocity, pwv), blood pressure (bp), wave reflection (aix), muscle strength and aerobic capacity in elderly women with stage 2 hypertension.

using a parallel experimental design, participants were randomly assigned to either swm (n=52) or non-exercising control group (n=48) for 20 weeks. participant in the swm group trained 3-4 days/week, progressing in duration from 25 to 45 min. participants' carotid to radial pwv (crpwv), systolic and diastolic bp, aix, strength and vo2max were measured at baseline and after 20 weeks of their assigned intervention.

Eligibility criteria:
inclusion criteria: * systolic/diastolic bp: 140-179 over 90-119 mm hg * had experienced the absence of menstruation for at least 1 year * body mass index \<30 kg/m2 * \<1 h of regular exercise per week in the previous year exclusion criteria: * smoker * taking any medications or hormone therapy in previous year

Keywords: swimming arterial stiffness blood pressure muscular strength cardiorespiratory endurance
a study of low-level light therapy using photo-activated modulation ameliorates cognitive deficits

Conditions: Mild Cognitive Impairment; Cerebral Blood Flow; Low-level Light Therapy; Brain Activity

Summary: the primary objective of this study is to confirm and compare the effect of methods of low-level light therapy (led-t) in the mild cognitive impairment.

total 168 patients were recruited and randomized to receive either real or sham-led-t. real experimental groups were divided into three groups; ca group, va group, ca+va dual group. each group received led-t (30 min) once a day for 30 days. each groups led-t positioned at following locations; * ca group on the superior border of the thyroid cartilage, and anterior to the sternocleidomastoid muscle based on korea traditional therapy called inyoung(st9) * va group on the upper abdomen, spinous process of the 2nd cervical vertebra upper margin based on korea traditional therapy called cunchu * ca+va dual group on the ca position (st9), and va position (bl10) the patients were initially evaluated at baseline, immediately, 4wks after intervention. study type : interventional study phase : not provided study design : allocation : randomized intervention model : parallel assignment masking : single blind (investigator) primary purpose : treatment, intervention condition : mild cognitive impairment, health subjects intervention : * low-level light therapy device (peak wavelength:610nm, power intensity: 1.7mw/cm2, energy density: 2.0j/cm2, skin-adhesive light-emitting probes: spot size, 1cm diameter), * parameters : neuroimaging assessement: fmri, spect, neuropsychological behavioral assessment: snsb; seoul neuropsychological screening battery, k-moca, corsi-block test, k-mbi, k-adl, gds, eq-5d, neurophysiological assessment: mep, motor evoked potential, gene test(bndf, apoe) study arms * experimental : sham control group and real stimulation group. * in each group, total sessions of the low-level light therapy (led-t) was done for intervention was followed after that. * subjects received led-t (30 min) once a day for 30 days. * the sham control group was kept without led-t

Eligibility criteria:
inclusion criteria: 1. subjects ages older than 55 years old 2. subjects who has k-moca assessment score less than 23 3. subjects who understand the purpose of the study and acquired the consent of the subjects or caregiver exclusion criteria: 1. subjects who have k-mmse less than 19 2. subjects who have pre-existing and present-existing neurological diseases as cns lesion 3. subjects who have psychiatric disease such as depression, schizophrenia, bipolar disease, or dementia 4. subjects who is estimated as not appropriate for the study by the investigators
blood compatibility characteristics of baxter xenium+, fresenius fx and gambro polyflux dialyzers

Conditions: End Stage Renal Failure on Dialysis

Summary: the aim of the dialyzer evaluation is to compare performance characteristics and haemocompatibility of the baxter xenium+ (polynephron), fresenius fx and gambro polyflux dialyzers

the xenium+ is a new high flux dialyzer made from polynephron membrane designed and manufactured by the nipro company in japan. this dialyzer has been subjected to in-vitro testing, and all legally required biological safety tests have been conducted and ce-mark was granted in june 2010. xenium+ has the same polynephron membrane as the xenium family of dialyzers which has been available commercially globally for approximately three years. clinical evaluations have been completed with the polynephron membrane within the last three years. the improvement in the xenium+ line is that the casing is now made from polypropylene. the aim of the dialyzer evaluation is to compare performance characteristics and hemocompatibility of the xenium+ (polynephron), fresenius fx and gambro polyflux dialyzers.

Eligibility criteria:
inclusion criteria: * esrd patients 18 years or older * stable on hemodialysis for more than 3 months * an average haematocrit value of 30 % or higher in the last three 3 months * stable vascular access of either a fistula or graft * stable anticoagulation and regimen * stable erythropoiesis-stimulating agent (esa) regimen for the last three 3 months * no active infection * able to sign informed consent and able to participate in the study * medically stable exclusion criteria: * participation in another study which may interfere with the planned study * active infection * medical conditions which may interfere with the study (cardiac, liver disease, hepatitis) * female(s) who are pregnant or planning to be pregnant * problem with or allergy to anticoagulation * central venous catheters

Keywords: hemodialysis high-flux-dialyzer performance blood compatibility
new ways to help patients improve their diabetes control

Conditions: Diabetes Mellitus

Summary: the percent of glycosylated hemoglobin, also known as a hemoglobin a1c value, is the standard way that clinicians assess a patient's diabetes control. numerous studies have shown that maintaining a hemoglobin a1c value less than 7% is associated with lower rates of diabetes-related complications. clinicians use this value to determine whether a patient with diabetes requires changes in their disease management. the main problem with this practice is that many patients do not understand what this number means. the goal of this project is to examine ways to make feedback about glycemic control easier for patients to understand. the hope is that improved patient understanding will result in an improvement in diabetic control and thus a reduction in disease-associated complications. patients with a diagnosis of diabetes and a hemoglobin a1c value greater than 8% within the preceding three months will be eligible for the study. pregnant women will be excluded. given the nature of the intervention we will also exclude patients with cognitive deficits. in this study, patients will be randomized to three groups. the first group with be told their hgba1c value only, the second group will be told a letter grade interpretation of that value, and the third group will be shown a face. the face emotions will range from happy to sad reflecting the level of control. the main outcome will be trend in hemoglobin a1c values over time. secondary outcomes will include patient understanding of disease state and the number of hemoglobin a1c values checked following the intervention.


Eligibility criteria:
inclusion criteria: 1. patients over the age of 18 with diabetes mellitus listed as a problem list or in their past medical history on their electronic medical record who have a hemoglobin a1c value greater than 8% within three months of study enrollment. exclusion criteria: 1. pregnant patients 2. illiterate patients 3. patients with known cognitive deficits affecting ability to participate in study 4. any current participants in another active research study
patent foramen ovale closure or medical therapy after stroke - respect trial

Conditions: Cryptogenic Stroke

Summary: the purpose of this study is to investigate whether percutaneous patent foramen ovale (pfo) closure, using the amplatzer pfo occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.

the amplatzer pfo occluder is a percutaneous, transcatheter occlusion device intended for the non-surgical closure of patent foramen ovale in subjects who have had a cryptogenic stroke due to presumed paradoxical embolism within the last 270 days.

Eligibility criteria:
inclusion criteria: * subjects who have had a cryptogenic stroke within the last 270 days * subjects who have been diagnosed with a patent foramen ovale (pfo) * subjects willing to participate in follow-up visits exclusion criteria: * subjects with intracardiac thrombus or tumor * subjects who have an acute or recent (within 6 months) myocardial infarction or unstable angina * subjects with left ventricular aneurysm or akinesis * subjects with atrial fibrillation/atrial flutter (chronic or intermittent) * subjects with another source of right to left shunt identified at baseline, including an atrial septal defect and/or fenestrated septum * subjects with contraindication to aspirin or clopidogrel therapy * pregnant or desire to become pregnant within the next year

Keywords: cryptogenic stroke pfo patent foramen ovale amplatzer occluder
remote ischemic preconditioning in cardiac surgery

Conditions: Ischemia Reperfusion Injury

Summary: aim of the work : evaluation of the role of remote ischemic preconditioning (rip) on liver function in patients undergoing on-pump cardiac surgery.


Eligibility criteria:
inclusion criteria: 1. being candidate for on-pump cardiac surgery. 2. willing to participate in the study 3. ages eligible for the study: 18 to 70 years. 4. gender eligible for the study : both exclusion criteria: 1. patient refusal. 2. known cause of possible liver function disturbances that includes right heart failure, acute inflammation of gallbladder or any other complication of gallstone disease. 3. active viral and non viral hepatitis. 4. pregnant women. 5. history of peripheral nerve disease or peripheral vascular disease of the extremities
breathing pattern, wob and gas exchange in patients with acute respiratory distress syndrome during the spontaneous breathing trial

Conditions: Work of Breathing; ARDS; Weaning Failure

Summary: there is little evidence about the mechanical characteristics and muscular function in patients with acute respiratory distress syndrome (ards) at the time of weaning of the mechanical ventilation, as well as the behavior of the mechanical properties, breathing pattern, muscular effort, and gas exchange during a successful and failed spontaneous breathing trial.

the study of the respiratory system (rs) mechanics in patients with ards has been focused on the initial phase of ventilatory support, with few studies observing the weaning in mechanical ventilation.the rs in patients with ards is characterized by a greater or lesser degree of low functional residual capacity (frc) in relation to normal. at the time of performing a spontaneous breathing trial, these mechanical characteristics determine the need to develop a high transpulmonary pressure during each breath, with high work of breathing (wob) to achieve adequate alveolar ventilation. inspiratory muscle weakness could alter the ability to generate the necessary transpulmonary pressure over time according to the loads imposed at the time of performing a spontaneous breathing trial, with the consequent development of fatigue and ventilatory failure. this is why the investigators propose to evaluate the association between elastic wob and the failure of the spontaneous breathing trial.

Eligibility criteria:
inclusion criteria: * over 18 years old * requiring mechanical ventilation for more than 12 hours * moderate/ severe ards according to berlin definition * able to make a spontaneous breathing trial according to the institution protocol exclusion criteria: * pregnant patients * history of neuromuscular disease * patients in palliative care * bronchopleural fistula * contraindication of measurement of esophageal pressure
instrument-assisted soft tissue mobilization and kinesiotape application in individuals with chronic neck pain.

Conditions: Cervical Pain

Summary: chronic neck pain causes errors in joint position sense. there are studies in the literature suggesting that instrument-assisted soft tissue mobilization and kinesiotape applications improve the joint position sense. there is no study examining these applications acutely on joint position sense and pain in the cervical region. as a result of our study, we will compare the effects of single-session instrument-assisted soft tissue mobilization and kinesiotape application on pain and joint position sense.

the study will be carried out on volunteers after the approval of the ethics committee. before the research, individuals and / or their relatives will be informed about the purpose and content of the study. volunteer individuals between the ages of 18-45 with chronic neck pain will be included in the study after obtaining their informed consent. participants will be randomly divided into two groups: instrument assisted soft tissue mobilization and kinesiotape applications. in the instrument-assisted soft tissue mobilization group, the trapezius and sternocleidomastoideus muscles will be applied in a single session for 90 seconds. kinesiotape application will be applied to the trapezius and sternocleidomastoideus muscles in one session. pain will be evaluated with visual analog scale and joint position sense will be evaluated with cervical range of motion device before and after application.

Eligibility criteria:
inclusion criteria: * being diagnosed with chronic neck pain * being in the age range of 18-45 exclusion criteria: * those with acute injury or infection, * those with open wounds, * osteoporosis, * hematoma, * those with acute cardiac, liver and kidney problems, * those with connective tissue disease, rheumatoid arthritis, osteoarthritis, cancer, * those with circulation problems, * those with peripheral vascular disease, * epilepsy * identified as a history of surgery in the cervical region

Keywords: chronic cervical pain instrument assisted soft tissue mobilization kinesiotape joint position sense
personalized, ct-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in non-atrial fibrillation patients after transcatheter aortic valve implantation

Conditions: Severe Aortic Valve Stenosis

Summary: the popular atlantis trial aims to investigate ct-guided antithrombotic therapy compared to lifelong single antiplatelet therapy after a transcatheter aortic valve implantation (tavi) procedure. only patients without an indication for anticoagulants will be included in this trial. currently, lifelong single antiplatelet therapy (mostly aspirin) is considered the standard of care for these patients. however, this approach poses a bleeding risk with only a minimal reduction in thromboembolic events. after 3 months, a ct scan will be conducted to assess the presence of thrombosis on the newly implanted tavi valve. based on the results of a 4d ct scan, the decision will be made whether the patient should receive no anticoagulant or antithrombotic therapy with apixaban. ct-guided antithrombotic therapy holds the potential for a greater reduction in thromboembolic events without increasing the bleeding risk.


Eligibility criteria:
inclusion criteria: * successful tavi (according to the varc-3 criteria)10 with any approved device * ability to understand and to comply with the study protocol * written informed consent exclusion criteria: * existing indication for oral anticoagulation (e.g. atrial fibrillation, obstructive valve thrombosis detected by echocardiography prior to inclusion) * existing indication for dual antiplatelet therapy at three months after tavi (rare at this time point) * creatinine clearance \<15 ml/min (based on the ckd-epi formula) or on renal replacement therapy

Keywords: aortic stenosis bleeding tavi ct personalized antithrombotic therapy tavr
the incidence of the intravascular injection during s1 transforaminal epidural steroid injection in two approaches: anteroposterior versus oblique

Conditions: Lumbosacral Radicular Pain

Summary: lumbosacral transforaminal epidural steroid injection (tfesi) is helpful for the treatment of lumbosacral radicular pain, but in case of intravascular injection, infrequently serious complication can be developed. against this backdrop, if there is any difference of frequency of intravascular injection incidence during s1 tfesi between method in anteroposterior view and method in oblique view using scotty dog, the result can be crucial factor in selecting the approach. in addition, appropriate volume of injection will be checked in each approach.


Eligibility criteria:
inclusion criteria: * adult patients (20-80 years of age) who were scheduled to receive s1 transforaminal epidural steroid injection for lumbosacral radicular pain at our pain management clinic exclusion criteria: * pregnancy * coagulopathy * systemic infection * any active infection at the injection site * history of allergy to contrast media, local anesthetics, corticosteroid * patients unable to communicate or patients with cognitive dysfunction

Keywords: epidural injections, intravascular injection